GLOW blend
GHK-Cu + BPC-157 + TB-500
GLOW is a compounded three-peptide mixture — GHK-Cu, BPC-157 and TB-500 — marketed for skin and connective-tissue support. Like KLOW, it has never been studied as a combination.
Regulatory status: Not an FDA-approved drug. It is a compounded mixture of three unapproved components, sold through the same unregulated channels as other peptide blends.
Default vial
70 mg
Default mix
3 mL
Reported range
500–1000 mcg of blend
Draw (U-100)
3 u
Skin/hair/tissue blend, typically GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg in one vial. Ratios vary by supplier — confirm the mg of each component on your COA.
What it is
- Three peptides in one vial: essentially KLOW without KPV.
- Ratios vary by supplier and are verifiable only through a Certificate of Analysis.
- No component holds FDA approval, and the combination has never been reviewed.
- Sold by peptide vendors and compounding pharmacies.
How it is described to act
- 1
Injected subcutaneously in practice; no studied regimen exists for the combination.
- 2
Each component behaves according to its own pharmacology; no combined data exist.
- 3
GHK-Cu is proposed to support collagen synthesis, BPC-157 to support tissue and gut repair in rodents, and TB-500 to aid cell migration in wound-healing models.
- 4
Combined 'synergy' for skin and tissue repair is a marketing claim, not a tested finding.
What the research has looked at
Component-level literature
- GHK-Cu skin-regeneration reviews (2015, 2020) and BPC-157 preclinical reviews (2020) describe each peptide separately.
- Thymosin beta-4 preclinical reviews describe tissue-repair roles for the parent protein of TB-500 (Expert Opin Biol Ther, 2018).
No blend-level evidence
- No PubMed or ClinicalTrials.gov record was located for the three-peptide combination.
Strength of evidence: Preclinical evidence only
No evidence exists for the blend; the component evidence is preclinical.
What is published comes from cell and animal studies. Findings in those models frequently do not carry over to people.
Reported cautions and unknowns
- There are no combined pharmacokinetic or toxicity data for any of these blends, so interaction risk is unquantified.
- The FDA's 2026 compounding-committee briefing on BPC-157 documented adverse-event reports and gaps in impurity characterisation for that single peptide.
- Sterility, identity and concentration of multi-peptide compounded vials vary by supplier; only a current third-party Certificate of Analysis can confirm what a vial actually contains.
References
Handling this vial
- As with any blend, the vial's total milligram figure is split across three peptides, so per-component dose cannot be read off a single draw volume.
- Lyophilized vials are generally stored at 2–8 °C and kept out of light; once reconstituted with bacteriostatic water they are refrigerated and commonly discarded after 28 days.
- Mix by aiming water down the vial wall and rolling gently — do not shake — and never re-freeze a reconstituted vial.
- Pep-Tidy cannot verify what is in your vial. Ask your supplier for a current Certificate of Analysis (HPLC/MS).
GLOW blend questions people ask
How do you reconstitute GLOW blend?
A common starting point for a 70 mg vial of GLOW blend is 3 mL of bacteriostatic water, which gives 23.33 mg per mL. Aim the water down the inside wall of the vial, let it dissolve on its own, and roll gently instead of shaking. Pep-Tidy's reconstitution calculator will recalculate the numbers for any other vial size or water volume you use.
How many units of GLOW blend is one dose?
At 23.33 mg per mL, that works out to about 3 units on a U-100 insulin syringe for a 700 mcg dose. Change the vial size, water volume, or target dose in the calculator and the syringe reading updates with it. This is arithmetic, not a dosing recommendation.
What dosing schedule is reported for GLOW blend?
Published and community sources describe 500–1000 mcg of blend, subcutaneous, every day, typically run 6 weeks on and 2 weeks off. These figures describe what has been reported, not what anyone should take — talk to a licensed clinician first.
How should GLOW blend be stored?
Lyophilized GLOW blend vials are generally kept at 2–8 °C and out of light. Once reconstituted with bacteriostatic water they are refrigerated and commonly discarded after about 28 days. Never re-freeze a reconstituted vial and never shake it.
Read this before you act on anything above
Everything on this page is a summary of what other people have published — it is not medical advice, not a recommendation, and not a dosing instruction. Reported dose ranges describe what appears in the literature or in community protocols, not what anyone should take. Talk to a licensed clinician before using any peptide.